Development of Therapy for Liver Fibrosis: Molecular/cellular basis and overcoming challenges
Author:
Affiliation:
1. Center for Matrix Biology and Medicine, Graduate School of Medicine, Tokai University
2. Institute of Medical Sciences, Tokai University
3. Department of Physiology, Tokai University School of Medicine
Publisher
Japan Society of Hepatology
Link
https://www.jstage.jst.go.jp/article/kanzo/65/7/65_305/_pdf
Reference55 articles.
1. 1) Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med 2024; 390 (6): 497-509
2. 2) Byrne CD, Targher G, Tilg H. Thyroid hormone receptor-beta agonists: new MASLD therapies on the horizon. Gut 2024; 73 (4): 573-581
3. 3) Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023; 79 (6): 1542-1556
4. 4) Harrison SA, Loomba R, Dubourg J, et al. Clinical trial landscape in NASH. Clin Gastroenterol Hepatol 2023; 21 (8): 2001-2014
5. 5) Chalasani N, Abdelmalek MF, Garcia-Tsao G, et al. Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension. Gastroenterology 2020; 158 (5): 1334-1345
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3